What 8 Analyst Ratings Have To Say About Gilead Sciences
Portfolio Pulse from Benzinga Insights
In the last three months, 8 analysts have published ratings on Gilead Sciences (NASDAQ:GILD), with a mix of bullish, somewhat bullish, and indifferent sentiments. The average 12-month price target is $79.5, with a high of $105.00 and a low of $69.00. Recent analyst actions include maintaining, lowering, and announcing new ratings, reflecting varied perspectives on Gilead's market position.
June 14, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Gilead Sciences (NASDAQ:GILD) has received mixed ratings from 8 analysts over the past three months, with an average 12-month price target of $79.5. Recent actions include maintaining, lowering, and announcing new ratings, indicating varied perspectives on the company's market position.
The mixed ratings and varied price targets suggest that analysts have differing views on Gilead's future performance. The average price target has declined by 5.03%, indicating some caution among analysts. However, the presence of both bullish and somewhat bullish ratings suggests that there is still optimism about the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100